000			01916nam a2200253Ia 4500
003			MX-MdCICY
005			20250626083336.0
040			_cCICY
090			_aB-21631
245	1	0	_aDesign, synthesis and biological evaluation of potent thiazolidinedione salicylic acid inhibitors against glyoxalase-I as potential anticancer agents
490	0		_aMedicinal Chemistry Research (2024) 33:1526-1540
500			_aArtículo
520	3		_aThe worldwide rise in cancer incidence and mortality rates has spurred the search for new pathways implicated in cancer development and progression. One such target is glyoxalase 1 (GLO-I), a key player in methylglyoxal detoxification and a factor in the proliferation and prognosis of numerous cancers. Recent studies led by Al-Shar'i et al. utilized computer-aided drug design to identify potential inhibitors of GLO-I. The second most potent hit, (Z)-5-(5-((2,4-dioxothiazolidin-5-ylidene) methyl)furan-2-yl)-2-hydroxybenzoic acid, (IC50 = 4.24 µM), was selected as a lead for further optimization. Through molecular docking, 27 analogs were designed and evaluated for binding affinity, with 14 of the top-scorings synthesized and tested for their inhibitory activity against GLO-I. The majority of these analogs showed enhanced activities relative to the lead compound, with the most potent having an IC50 of 150 nM. These findings pave the way for the continued development of highly effective GLO-I inhibitors.
650	1	4	_aGLO-I ENZYME
650	1	4	_aMOLECULAR DOCKING
650	1	4	_aARYL SALICYLIC ACID
700	1	2	_aAlomari, B. O.
700	1	2	_aFakhouri, L. I.
700	1	2	_aAl‑Shar'i, N. A.
700	1	2	_aAlbalas, Q.
856	4	0	_uhttps://drive.google.com/file/d/1OcpN2jN8y3WnnVYqTZlL_Ed-DDNmNmwh/view?usp=drive_link _zPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx
942			_2Loc _cREF1
008			250602s9999 xx |||||s2 |||| ||und|d
999			_c55698 _d55698